Tumor-associated Carbonic Anhydrases and Their Clinical Significance

Advances in Clinical Chemistry

Volumn 42, Issue , 2006, Pages 167-216

  Pastorekova, Silvia ^a   Parkkila, Seppo ^b,c   Zavada, Jan ^d  

^a INSTITUTE OF VIROLOGY   (Slovakia)

^b UNIVERSITY OF TAMPERE   (Finland)

^c UNIVERSITY OF OULU   (Finland)

^d INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

CARBONATE DEHYDRATASE;

ENZYMOLOGY; HUMAN; METABOLISM; NEOPLASM; REVIEW;

CARBONIC ANHYDRASES; HUMANS; NEOPLASMS;

EID: 33748079158     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2423(06)42005-9     Document Type: Review

References (203)

1. Supuran C. Carbonic anhydrases: Catalytic mechanisms, distribution and physiological roles. In: Supuran C., Scozzafava A., and Conway J. (Eds). Carbonic anhydrase: Its inhibitors and activators (2004), CRC Press, Boca Raton 1-24
2. Pastorekova S., Parkkila S., Pastorek J., and Supuran C. Carbonic anhydrases: Current state of the art, therapeutic applications and future prospects. J Enz Inhib Med Chem 19 (2004) 199-229
3. Hilvo M., Tolvanen M., Clark A., Shen B., Shah G., Waheed A., et al. Characterization of CA XV, a new GPI-anchored form of carbonic anhydrase. Biochem J 392 (2005) 83-92
4. Peles E., Nativ M., Campbell P., Sakurai T., Martinez R., Lev S., et al. The carbonic anhydrase domain of receptor tyrosine phosphatase beta is a functional ligand for the axonal cell recognition molecule contactin. Cell 82 (1995) 251-260
5. Lehtonen J., Shen B., Vihinen M., Casini A., Scozzafava A., Supuran C., et al. Characterization of CA XIII, a novel member of the carbonic anhydrase isozyme family. J Biol Chem 279 (2004) 2719-2727
6. Parkkila S. An overview of the distribution and function of carbonic anhydrase in mammals. In: Chegwidden W., Carter N., and Edwards Y. (Eds). The Carbonic Anhydrases: New Horizons (2000), Birkhauser Verlag, Basil 76-93
7. Sly W., Waheed A., Shah G., and Zhou X. Functional genomics of the mitochondrial carbonic anhydrases. Abstract book from The 6th International Conference on the Carbonic Anhydrases, June 20-25 (2003) Smolenice castle, Slovak Republic, Abstract L20
8. McMurtrie H., Cleary H., Alvarez B., Loiselle F., Sterling D., Morgan P., et al. The bicarbonate transport metabolon. J Enz Inhib Med Chem 19 (2004) 231-236
9. Alvarez B., Vilas G., and Casey J. Metabolon disruption: A mechanism that regulated bicarbonate transport. EMBO J 24 (2005) 2499-2511
10. - exchanger. J Biol Chem 273 (1998) 28430-28437
11. - anion exchanger AE1. Biochemistry 39 (2000) 5527-5533
12. Sterling D., Reithmeier R., and Casey J. A transport metabolon. Functional interaction of carbonic anhydrase II and chloride/bicarbonate exchangers. J Biol Chem 276 (2001) 47886-47894
13. Gross E., Pushkin A., Abuladze N., Fedotoff O., and Kurtz I. Regulation of the sodium bicarbonate cotransporter kNBC1 function: Role of Asp(986), Asp(988) and kNBC1-carbonic anhydrase II binding. J Physiol 544 (2002) 679-685
14. - exchanger binds carbonic anhydrase IV. J Biol Chem 277 (2002) 25239-25246
15. Alvarez B., Loiselle F., Supuran C., Schwartz G., and Casey J. Direct extracellular interaction between carbonic anhydrase IV and the human NBC1 sodium/bicarbonate co-transporter. Biochemistry 42 (2003) 12321-12329
16. Sly W., and Hu P. Human carbonic anhydrases and carbonic anhydrase deficiencies. Annu Rev Biochem 64 (1995) 375-401
17. Supuran C., and Scozzafava A. Carbonic anhydrase inhibitors and their therapeutic potential. Expert Opin Ther Patents 10 (2000) 575-600
18. Kummola L., Hamalainen J., Kivela J., Kivela A., Saarnio J., Karttunen T., et al. Expression of a novel carbonic anhydrase, CA XIII, in normal and neoplastic colorectal mucosa. BMC Cancer 5 (2005) 41
19. Kuo W., Chiang W., Yang S., Yeh K., Yeh C., Hsieh Y., et al. The differential expression of cytosolic carbonic anhydrase in human hepatocellular carcinoma. Life Sci 73 (2003) 2211-2223
20. Chiang W., Chu S., Yang S., Li M., Lai J., Yang S., et al. The aberrant expression of cytosolic carbonic anhydrase and its clinical significance in human non-small cell lung cancer. Cancer Lett 188 (2002) 199-205
21. Kivela A., Saarnio J., Karttunen T., Kivela J., Parkkila A., Pastorekova S., et al. Differential expression of cytoplasmic carbonic anhydrases, CA I and II, and membrane-associated isozymes, CA IX and XII, in normal mucosa of large intestine and in colorectal tumors. Dig Dis Sci 46 (2001) 2179-2186
22. Mori M., Staniunas R., Barnard G., Jessup J., Steele Jr. G., and Chen L. The significance of carbonic anhydrase expression in human colorectal cancer. Gastroenterology 105 (1993) 820-826
23. Akisawa Y., Nishimori I., Taniuchi K., Okamoto N., Takeuchi T., Sonobe H., et al. Expression of carbonic anhydrase-related protein CA-RP VIII in non-small cell lung cancer. Virchows Arch 442 1 (2003) 66-70
24. Miyaji E., Nishimori I., Taniuchi K., Takeuchi T., Ohtsuki Y., and Onishi S. Overexpression of carbonic anhydrase-related protein VIII in human colorectal cancer. J Pathol 201 1 (2003) 37-45
25. Lu S., Takeuchi T., Fujita J., Ishida T., Akisawa Y., Nishimori I., et al. Effect of carbonic anhydrase-related protein VIII expression on lung adenocarcinoma cell growth. Lung Cancer 44 3 (2004) 273-280
26. Pastorekova S., and Pastorek J. Cancer-related carbonic anhydrase isozymes and their inhibition. In: Supuran C., Scozzafava A., and Conway J. (Eds). Carbonic Anhydrase, Its Inhibitors and Activators (2004), CRC Press, Boca Raton 253-279
27. Pastorekova S., and Zavada J. Carbonic anhydrase IX (CA IX) as a potential target for cancer therapy. Review article. On-line:. www.cancer-therapy.org.
28. Pastorekova S., and Zavada J. Carbonic anhydrase IX (CA IX) as a potential target for cancer therapy. Review article. On-line:. Cancer Ther 2 (2004) 245-262
29. Zavada J. The pseudotypic paradox: Review article. J Gen Virol 63 (1982) 15-24
30. Pastorekova S., Zavadova Z., Kostal M., Babusikova O., and Zavada J. A novel quasi-viral agent, MaTu, is a two-component system. Virology 187 (1992) 620-626
31. Zavada J., Zavadova Z., Pastorekova S., Ciampor F., Pastorek J., and Zelnik V. Expression of MaTu-MN protein in human tumor cultures and in clinical specimens. Int J Cancer 54 (1993) 268-274
32. Pastorek J., Pastorekova S., Callebaut I., Mornon J., Zelnik V., Opavsky R., et al. Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and putative helix-loop-helix DNA binding segment. Oncogene 9 (1994) 2877-2888
33. Opavsky R., Pastorekova S., Zelnik V., Gibadulinova A., Stanbridge E., Zavada J., et al. Human MN/CA9 gene, a novel member of the carbonic anhydrase family: Structure and exon to protein domain relationships. Genomics 33 (1996) 480-487
34. Wingo T., Tu C., Laipis P., and Silverman D. The catalytic properties of human carbonic anhydrase IX. Biochem Biophys Res Commun 288 (2001) 666-669
35. Vullo D., Franchi M., Gallori E., Pastorek J., Scozzafava A., Pastorekova S., et al. Carbonic anhydrase inhibitors. Inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides. Bioorg Med Chem Lett 13 (2003) 1005-1009
36. Ilies M., Vullo D., Pastorek J., Scozzafava A., Ilies M., Caproiu M., et al. Carbonic anhydrase inhibitors. Inhibition of tumor-associated isozyme IX by halogenosulfanilamide and halogenophenylaminobenzolamide derivatives. J Med Chem 46 (2003) 2187-2196
37. Franchi M., Vullo D., Gallori E., Pastorek J., Russo A., Scozzafava A., et al. Carbonic anhydrase inhibitors. Inhibition of cytosolic isozymes I and II and transmembrane, cancer-associated isozyme IX with lipophilic sulfonamides. J Enzyme Inhib Med Chem 18 (2003) 333-338
38. Vullo D., Scozzafava A., Pastorekova S., Pastorek J., and Supuran C. Carbonic anhydrase inhibitors: Inhibition of the tumor-associated isozyme IX with fluorine-containing sulfonamides. The first subnanomolar CA IX inhibitor discovered. Bioorg Med Chem Lett 14 (2004) 2351-2356
39. Winum J., Vullo D., Casini A., Montero J., Scozzafava A., and Supuran C. Carbonic anhydrase inhibitors. Inhibition of cytosolic isozymes I and II and transmembrane, tumor-associated isozyme IX with sulfamates including EMATE also acting as steroid sulfatase inhibitors. J Med Chem 46 (2003) 2197-2204
40. Casey J., Morgan P., Vullo D., Scozzafava A., Mastrolorenzo A., and Supuran C. Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX. J Med Chem 47 (2004) 2337-2347
41. Zavada J., Zavadova Z., Pastorek J., Biesova Z., Jezek J., and Velek J. Human tumour-associated cell adhesion protein MN/CA IX: Identification of M75 epitope and of the region mediating cell adhesion. Br J Cancer 82 (2000) 1808-1813
42. Oosterwijk E., Ruiter D., Hoedemaeker P., Pauwels E., Jonas U., Zwartendijk J., et al. Monoclonal antibody G250 recognizes determinant present in renal cell carcinoma and absent from normal kidney. Int J Cancer 38 (1986) 489-494
43. Grabmaier K., Vissers J., De Weijert M., Oosterwijk-Wakka J., Van Bokhoven A., Brakenhoff R., et al. Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. Int J Cancer 85 (2000) 865-870
44. Zatovicova M., Tarabkova K., Svastova E., Gibadulinova A., Mucha V., Jakubickova L., et al. Monoclonal antibodies generated in CA IX-deficient mice recognize different domains of tumor-associated hypoxia-induced carbonic anhydrase IX. J Immunol Methods 282 (2003) 117-134
45. Ivanov S., Liao S., Ivanova A., Danilkovitch-Miagkova A., Tarasova T., Weirich G., et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 158 (2001) 905-919
46. Zavadova Z., and Zavada J. Carbonic anhydrase IX (CA IX) mediates tumor cell interactions with microenvironment. Oncol Reports 13 (2005) 977-982
47. Wykoff C., Beasley N., Watson P., Turner K., Pastorek J., Sibtain A., et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 60 (2000) 7075-7083
48. Chrastina A., Zavada J., Parkkila S., Kaluz S., Kaluzova M., Rajcani J., et al. Biodistribution and pharmacokinetics of 125I-labeled monoclonal antibody M75 specific for carbonic anhydrase IX, an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinoma. Int J Cancer 105 (2003) 873-881
49. Gut M., Parkkila S., Vernerova Z., Rohde E., Zavada J., Hocker M., et al. Gastric hyperplasia in mice with targeted disruption of the carbonic anhydrase gene Car9. Gastroenterology 123 (2002) 1889-1903
50. Pastorekova S., Parkkila S., Parkkila A., Opavsky R., Zelnik V., Saarnio J., et al. Carbonic anhydrase IX, MN/CA IX: Analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts. Gastroenterology 112 (1997) 398-408
51. Hilvo M., Rafajova M., Pastorekova S., Pastorek J., and Parkkila S. Expression of carbonic anhydrase IX in mouse tissues. J Histochem Cytochem 52 (2004) 1313-1322
52. Leppilampi M., Saarnio J., Tuomo J., Kivela J., Pastorekova S., Pastorek J., et al. Carbonic anhydrase isoenzymes IX and XII in gastric tumors. World J Gastroenterol 9 (2003) 1398-1403
53. Chen J., Röcken C., Hoffmann J., Krüger S., Lendeckel U., Rocco A., et al. Expression of carbonic anhydrase 9 at the invasion front of gastric cancers. Gut 54 (2005) 920-927
54. Saarnio J., Parkkila S., Parkkila A., Pastorekova S., Haukipuro K., Pastorek J., et al. Transmembrane carbonic anhydrase, MN/CA IX, is a potential biomarker for biliary tumors. J Hepatol 35 (2001) 643-649
55. Kivela A., Parkkila S., Saarnio J., Karttunen T., Kivela J., Parkkila A., et al. Expression of transmembrane carbonic anhydrase isoenzymes IX and XII in normal human pancreas and pancreatic tumours. Histochem Cell Biol 114 (2000) 197-204
56. Juhasz M., Chen J., Lendeckel U., Kellner U., Kasper H., Tulassay Z., et al. Expression of carbonic anhydrase IX in human pancreatic cancer. Aliment Pharmacol Ther 18 (2003) 1-10
57. Saarnio J., Parkkila S., Parkkila A., Waheed A., Casey M., Zhou X., et al. Immunochemistry of carbonic anhydrase isozyme IX (MN/CA IX) in human gut reveals polarized expression in the epithelial cells with the highest proliferative capacity. J Histochem Cytochem 46 (1998) 497-504
58. Saarnio J., Parkkila S., Parkkila A., Haukipuro K., Pastorekova S., Pastorek J., et al. Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation. Am J Pathol 153 (1998) 279-285
59. Karhumaa P., Kaunisto K., Parkkila S., Waheed A., Pastorekova S., Pastorek J., et al. Expression of the transmembrane carbonic anhydrases, CA IX and CA XII, in the human male excurrent ducts. Mol Hum Reprod 7 (2001) 611-616
60. Liao S., Brewer C., Zavada J., Pastorek J., Pastorekova S., Manetta A., et al. Identification of the MN antigen as a diagnostic biomarker of cervical intraepithelial squamous and glandular neoplasia and cervical carcinomas. Am J Pathol 145 (1994) 598-609
61. Liao S., and Stanbridge E. Expression of the MN antigen in cervical Papanicolaou smears is an early diagnostics biomarker of cervical dysplasia. Cancer Epidemiol Biomarkers Prev 5 (1996) 549-557
62. McKiernan J., Buttyan R., Bander N., Stifelman M., Katz A., Chen M., et al. Expression of the tumor-associated gene MN: A potential biomarker for human renal cell carcinoma. Cancer Res 57 (1997) 2362-2365
63. Liao S., Aurelio O., Jan K., Zavada J., and Stanbridge E. Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res 57 (1997) 2827-2831
64. Uemura H., Nakagawa Y., Yoshida K., Saga S., Yoshikawa K., Hirao Y., et al. MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas. Br J Cancer 81 (1999) 741-746
65. Turner J., Odze R., Crum C., and Resnick M. MN antigen expression in normal, preneoplastic, and neoplastic esophagus: A clinicopathological study of a new cancer-associated biomarker. Hum Pathol 28 (1997) 740-744
66. Vermylen P., Roufosse C., Burny A., Verhest A., Bosschaerts T., Pastorekova S., et al. Carbonic anhydrase IX antigen differentiates between preneoplastic lesions in non-small-cell lung carcinoma. Eur Respir J 14 (1999) 806-811
67. Bartosova M., Parkkila S., Pohlodek K., Karttunen T., Galbavy S., Mucha V., et al. Expression of carbonic anhydrase IX in breast is associated with malignant tissues and is related to overexpression of c-erbB2. J Pathol 197 (2002) 314-321
68. Haapasalo J., Nordfors K., Hilvo M., Rantala I., Soini Y., Parkkila A., et al. Expression of carbonic anhydrase IX in astrocytic tumors predicts poor prognosis. Clin Cancer Res 12 (2005) 473-477
69. Kowalewska M., Radziszewski J., Kulik J., Barathova M., Nasierowska-Guttmajer A., Bidzinski M., et al. Detection of carbonic anhydrase 9-expressing tumor cells in the lymph nodes of vulvar carcinoma patients by RT-PCR. Int J Cancer 116 (2005) 957-962
70. Torczynski R., and Bollon A. Gene sequence and probe for a marker of non-small cell lung carinoma. United States patent (1996) 5,589,579
71. Tureci O., Sahin U., Vollmar E., Siemer S., Gottert E., Seitz G., et al. Human carbonic anhydrase XII: cDNA cloning, expression, and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cell cancers. Proc Natl Acad Sci USA 95 (1998) 7608-7613
72. Ivanov S., Kuzmin I., Wei M., Pack S., Geil L., Johnson B., et al. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc Natl Acad Sci USA 95 (1998) 12596-12601
73. Ulmasov B., Waheed A., Shah G., Grubb J., Sly W., Tu C., et al. Purification and kinetic analysis of recombinant CA XII, a membrane carbonic anhydrase overexpressed in certain cancers. Proc Natl Acad Sci USA 97 (2000) 14212-14217
74. Whittington D., Waheed A., Ulmasov B., Shah G., Grubb J., Sly W., et al. Crystal structure of the dimeric extracellular domain of human carbonic anhydrase XII, a bitopic membrane protein overexpressed in certain cancer tumor cells. Proc Natl Acad Sci USA 98 (2000) 9545-9550
75. Karhumaa P., Parkkila S., Tureci O., Waheed A., Grubb J., Shah G., et al. Identification of carbonic anhydrase XII as the membrane isozyme expressed in the normal human endometrial epithelium. Mol Hum Reprod 6 (2000) 68-74
76. Parkkila S., Parkkila A., Saarnio J., Kivela J., Karttunen T., Kaunisto K., et al. Expression of the membrane-associated carbonic anhydrase isozyme XII in the human kidney and renal tumors. J Histochem Cytochem 48 (2000) 1601-1608
77. Kyllonen M., Parkkila S., Rajaniemi H., Waheed A., Grubb J., Shah G., et al. Localization of carbonic anhydrase XII to the basolateral membrane of H+-secreting cells of mouse and rat kidney. J Histochem Cytochem 51 (2003) 1217-1224
78. Kivela A., Parkkila S., Saarnio J., Karttunen T., Kivela J., Parkkila A., et al. Expression of a novel transmembrane carbonic anhydrase isozyme XII in normal human gut and colorectal tumors. Am J Pathol 156 (2000) 577-584
79. Halmi P., Lehtonen J., Waheed A., Sly W., and Parkkila S. Expression of hypoxia-inducible, membrane-bound carbonic anhydrase isozyme XII in mouse tissues. Anat Rec 277A (2004) 171-177
80. Lieskovska J., Opavsky R., Zacikova L., Glasova M., Pastorek J., and Pastorekova S. Study of in vitro conditions modulating expression of MN/CA IX protein in human cell lines derived from cervical carcinoma. Neoplasma 46 (1999) 17-24
81. Kaluz S., Kaluzova M., Opavsky R., Pastorekova S., Gibadulinova A., Dequiedt F., et al. Transcriptional regulation of the MN/CA9 gene coding for the tumor-associated carbonic anhydrase IX. Identification and characterization of a proximal silencer element. J Biol Chem 274 (1999) 32588-32595
82. Kaluzova M., Pastorekova S., Svastova E., Pastorek J., Stanbridge E., and Kaluz S. Characterization of the MN/CA 9 promoter proximal region: A role for specificity protein (SP) and activator protein 1 (AP1) factors. Biochem J 359 (2001) 669-677
83. Maxwell P., Wiesener M., Chang G., Clifford S., Vaux E., Cockman M., et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 (1999) 271-275
84. Epstein A., Gleadle J., McNeil L., Hewitson K., O'Rourke J., Mole D., et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107 (2001) 43-54
85. Jaakkola P., Mole D., Tian Y., Wilson M., Gielbert J., Gaskell S., et al. Targeting of HIFα to the von Hippel Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292 (2001) 468-472
86. Ivan M., Kondo K., Yang H., Kim W., Valiando J., Ohh M., et al. HIFα targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing. Science 292 (2001) 464-468
87. Lando D., Peet D., Gorman J., Whelan D., Whitelaw M., and Bruick R. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev 6 (2002) 1466-1471
88. Harris A. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2 (2002) 38-47
89. Semenza G. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3 (2003) 721-732
90. Lal A., Peters H., St Croix B., Haroon Z., Dewhirst M., Strausberg R., et al. Transcriptional response to hypoxia in human tumors. J Natl Cancer Inst 93 (2001) 1337-1343
91. Blais J., Filipenko V., Bi M., Harding H., Ron D., Koumenis C., et al. Activating transcription factor 4 is translationally regulated by hypoxic stress. Mol Cell Biol 24 (2004) 7469-7482
92. Kaluz S., Kaluzova M., Chrastina A., Olive P., Pastorekova S., Pastorek J., et al. Lowered oxygen tension induces expression of the hypoxia marker MN/carbonic anhydrase IX in the absence of hypoxia-inducible factor 1α stabilization: A role for phosphatidylinositol 3′-kinase. Cancer Res 62 (2002) 4469-4477
93. Dery M., Michaud M., and Richard D. Hypoxia-inducible factor 1: Regulation by hypoxic and non-hypoxic activators. Int J Biochem Cell Biol 37 (2005) 535-540
94. Kopacek J., Barathova M., Dequiedt F., Sepelakova J., Kettmann R., Pastorek J., et al. MAPK pathway contributes to density- and hypoxia-induced expression of the tumor-associated carbonic anhydrase IX. Biochim Biophys Acta 1729 (2005) 41-49
95. Kaluz S., Kaluzova M., and Stanbridge E. Expression of the hypoxia marker carbonic anhydrase IX is critically dependent on SP1 activity. Identification of a novel type of hypoxia-responsive enhancer. Cancer Res 63 (2003) 917-922
96. Kaluzova M., Kaluz S., Lerman M., and Stanbridge E. DNA damage is a prerequisite for p53-mediated proteasomal degradation of HIF-1alpha in hypoxic cells and downregulation of the hypoxia marker carbonic anhydrase IX. Mol Cell Biol 24 (2004) 5757-5766
97. Mandriota S., Turner K., Davies D., Murray P., Morgan N., Sowter H., et al. HIF activation identifies early lesions in VHL kidneys: Evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 1 (2002) 459-468
98. Cho M., Grabmaier K., Kitahori Y., Hiasa Y., Nakagawa Y., Uemura H., et al. Activation of the MN/CA9 gene is associated with hypomethylation in human renal cell carcinoma cell lines. Mol Carcinogen 27 (2000) 184-189
99. Ashida S., Nishimori I., Tanimura M., Onishi S., and Shuin T. Effects of von Hippel-Lindau gene mutation and methylation status on expression of transmembrane carbonic anhydrases in renal cell carcinoma. J Cancer Res Clin Oncol 128 (2002) 561-568
100. Grabmaier K., de Weijert M., Uemura H., Schalken J., and Oosterwijk E. Renal cell carcinoma-associated G250 methylation and expression: In vivo and in vitro studies. Urology 60 (2002) 357-362
101. Jakubickova L., Biesova Z., Pastorekova S., Kettmann R., and Pastorek J. Methylation of the CA9 promoter can modulate expression of the tumor-associated carbonic anhydrase IX in dense carcinoma cell lines. Int J Oncol 26 (2005) 1121-1127
102. Rafajova M., Zatovicova M., Kettmann R., Pastorek J., and Pastorekova S. Induction by hypoxia combined with low glucose or low bicarbonate and high posttranslational stability upon reoxygenation contribute to carbonic anhydrase IX expression in cancer cells. Int J Oncol 24 (2004) 995-1004
103. Vordermark D., Kaffer A., Riedl S., Katzer A., and Flentje M. Characterization of carbonic anhydrase IX (CA IX) as an endogenous marker of chronic hypoxia in live human tumor cells. Int J Radiat Oncol Biol Phys 61 (2005) 1197-1207
104. Sobhanifar S., Aquino-Parsons C., Stanbridge E., and Olive P. Reduced expression of hypoxia-inducible factor-1α in perinecrotic regions of solid tumors. Cancer Res 65 (2005) 7259-7266
105. Zavada J., Zavadova Z., Zatovicova M., Hyrsl L., and Kawaciuk I. Soluble form of carbonic anhydrase IX (CA IX) in the serum and urine of renal carcinoma patients. Br J Cancer 89 (2003) 1067-1071
106. Zatovicova M., Sedlakova O., Svastova E., Ohradanova A., Ciampor F., Arribas J., et al. Ectodomain shedding of the hypoxia-induced carbonic anhydrase IX is a metalloprotease-dependent process regulated by TACE/ADAM17. Br J Cancer 93 (2005) 1267-1276
107. Wiesener M., Munchenhagen P., Berger I., Morgan N., Roigas J., Schwiertz A., et al. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1α in clear cell renal carcinomas. Cancer Res 61 (2001) 5215-5222
108. Bui M., Seligson D., Han K., Pantuck A., Dorey F., Huang Y., et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: Implications for prognosis and therapy. Clin Cancer Res 9 (2003) 802-811
109. Bui M., Visapaa H., Seligson D., Kim H., Han K., Huang Y., et al. Prognostic value of carbonic anhydrase IX and Ki67 as predictors of survival for renal clear cell carcinoma. J Urol 171 (2004) 2461-2466
110. Raval R., Lau K., Tran M., Sowter H., Mandriota S., Li J., et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 25 (2005) 5675-5686
111. Hu C., Wang L., Chodosh L., Keith B., and Simon M. Differential roles of hypoxia-inducible factor 1α (HIF-1α) and HIF-2α in hypoxic gene regulation. Mol Cell Biol 23 (2003) 9361-9374
112. Brouwers A., Frielink C., Oosterwijk E., Oyen W., Corstens F., and Boerman O. Interferons can upregulate the expression of the tumor associated antigen G250-MN/CA IX, a potential target for (radio)immunotherapy of renal cell carcinoma. Cancer Biother Radiopharm 18 (2003) 539-547
113. Atkins M., Regan M., McDermott D., Mier J., Stanbridge E., Youmans A., et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res. 11 (2005) 3714-3721
114. Pantuck A., Zeng G., Belldegrun A., and Figlin R. Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: Exploiting the hypoxia-induced pathway. Clin Cancer Res 9 (2003) 4641-4652
115. Soyupak B., Erdogan S., Ergin M., Seydaoglu G., Kuzgunbay B., and Tansug Z. CA9 expression as a prognostic factor in renal clear cell carcinoma. Urol Int 74 (2005) 68-73
116. Loncaster J., Harris A., Davidson S., Logue J., Hunter R., Wykoff C., et al. Carbonic anhydrase IX expression, a potential new intrinsic marker of hypoxia: Correlations with tumour oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 61 (2001) 6394-6399
117. Olive P., Aquino-Parsons C., MacPhail S., Laio S., Raleigh J., Lerman M., et al. Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer. Cancer Res 61 (2001) 8924-8929
118. Airley R., Loncaster J., Raleigh J., Harris A., Davidson S., Hunter R., et al. GLUT-1 and CA IX as intrinsic markers of hypoxia in carcinoma of the cervix: Relationship to pimonidazole binding. Int J Cancer 104 (2003) 85-91
119. Wykoff C., Beasley N., Watson P., Campo L., Chia S., English R., et al. Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. Am J Pathol 158 (2001) 1011-1019
120. Chia S., Wykoff C., Watson P., Han C., Leek R., Pastorek J., et al. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol 19 (2001) 3660-3668
121. Giatromanolaki A., Koukourakis M., Sivridis E., Pastorek J., Wykoff C., Gatter K., et al. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res 61 (2001) 7992-7998
122. Beasley N., Wykoff C., Watson P., Leek R., Turley H., Gatter K., et al. Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis and microvessel density. Cancer Res 61 (2001) 5262-5267
123. Turner K., Crew J., Wykoff C., Watson P., Poulsom R., Pastorek J., et al. The hypoxia-inducible genes VEGF and CA9 are differentially regulated in superficial vs invasive bladder cancer. Br J Cancer 86 (2002) 1276-1282
124. Hui E., Chan A., Pezzella F., Turley H., To K., Poon T., et al. Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res 8 (2002) 2595-2604
125. Hoskin P., Sibtain A., Daley F., and Wilson G. GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: Relationship with vascularity and proliferation as predictors of outcome of ARCON. Br J Cancer 89 (2003) 1290-1297
126. Swinson D., Jones J., Cox G., Richardson D., Harris A., and O'Byrne K. Hypoxia-inducible factor-1 alpha in non small cell lung cancer: Relation to growth factor, protease and apoptosis pathways. Int J Cancer 111 (2004) 43-50
127. Hutchison G., Valentine H., Loncaster J., Davidson S., Hunter R., Roberts S., et al. Hypoxia-inducible factor 1alpha expression as an intrinsic marker of hypoxia: Correlation with tumor oxygen, pimonidazole measurements, and outcome in locally advanced carcinoma of the cervix. Clin Cancer Res 10 (2004) 8405-8412
128. Vleugel M., Greijer A., Shvarts A., van der Groep P., van Berkel M., Aarbodem Y., et al. Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer. J Clin Pathol 58 (2005) 172-177
129. De Schutter H., Landuyt W., Verbeken E., Goethals L., Hermans R., and Nuyts S. The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/- chemotherapy. BMC Cancer 5 (2005) 42
130. Kim S., Rabbani Z., Dewhirst M., Vujaskovic Z., Vollmer R., Schreiber E., et al. Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. Lung Cancer 49 3 (2005) 325-335
131. Sorensen B., Hao J., Overgaard J., Vorum H., Honore B., Alsner J., et al. Influence of oxygen concentration and pH on expression of hypoxia induced genes. Radiother Oncol 76 2 (2005) 187-193
132. Vukovic V., Haugland H., Nicklee T., Morrison A., and Hedley D. Hypoxia-inducible factor-1α is an intrinsic marker for hypoxia in cervical cancer xenografts. Cancer Res 61 (2001) 7394-7398
133. Ord J., Streeter E., Roberts I., Cranston D., and Harris A. Comparison of hypoxia transcriptome in vitro with in vivo gene expression in human bladder cancer. Br J Cancer 93 (2005) 1-9
134. Hockel M., and Vaupel P. Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93 (2001) 266-276
135. Hedley D., Pintilie M., Woo J., Morrison A., Birle D., Fyles A., et al. Carbonic anhydrase IX expression, hypoxia, and prognosis in patients with uterine cervical carcinomas. Clin Cancer Res 9 (2003) 5666-5674
136. Stone J., Parker R., Gilks C., Stanbridge E., Liao S., and Aquino-Parsons C. Intratumoral oxygenation of invasive squamous cell carcimoma of the vulva is not correlated with regional lymph node metastasis. Eur J Gynaecol Oncol 26 (2005) 31-35
137. Colpaert C., Vermeulen P., Van Beest P., Soubry A., Goovaerts G., Dirix L., et al. Cutaneous breast cancer deposits show distinct growth patterns with different degrees of angiogenesis, hypoxia and fibrin deposition. Histopathology 42 (2003) 530-540
138. Span P., Bussink J., Manders P., Beex L., and Sweep C. Carbonic anhydrase-9 expression levels and prognosis in human breast cancer: Association with treatment outcome. Br J Cancer 89 (2003) 271-276
139. Swinson D., Jones J., Richardson D., Wykoff C., Turley H., Pastorek J., et al. Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J Clin Oncol 21 (2003) 473-482
140. Kim S., Rabbani Z., Vollmer R., Schreiber E., Oosterwijk E., Dewhirst M., et al. Carbonic anhydrase IX in early-stage non-small cell lung cancer. Clin Cancer Res 10 (2004) 7925-7933
141. Koukourakis M., Giatromanolaki A., Sivridis E., Simopoulos K., Pastorek J., Wykoff C., et al. Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin Cancer Res 7 (2001) 3399-3403
142. Hoogsteen I., Marres H., Wijffels K., Rijken P., Peters J., van den Hoogen F., et al. Colocalization of carbonic anhydrase 9 expression and cell proliferation in human head and neck squamous cell carcinoma. Clin Cancer Res 11 (2005) 97-106
143. Maseide K., Kandel R., Bell R., Catton C., O'Sullivan B., Wunder J., et al. Carbonic anhydrase IX as a marker for poor prognosis in soft tissue sarcoma. Clin Cancer Res 10 (2004) 4464-4471
144. Swinson D., Cox G., and O'Byrne K. Coexpression of epidermal growth factor receptor with related factors is associated with a poor prognosis in non-small-cell lung cancer. Br J Cancer 91 (2004) 1301-1307
145. Watson P., Chia S., Wykoff C., Han C., Leek R., Sly W., et al. Carbonic anhydrase XII is a marker of good prognosis in invasive breast carcinoma. Br J Cancer 88 (2003) 1065-1070
146. Robertson N., Potter C., and Harris A. Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion. Cancer Res 64 (2004) 6160-6165
147. Svastova E., Zilka N., Zatovicova M., Gibadulinova A., Ciampor F., Pastorek J., et al. Carbonic anhydrase IX reduces E-cadherin-mediated adhesion of MDCK cells via interaction with β-catenin. Exp Cell Res 290 (2003) 332-345
148. Svastova E., Hulikova A., Rafajova M., Zat'ovicova M., Gibadulinova A., Casini A., et al. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett 577 (2004) 439-495
149. Morgan P., Pastorekova S., and Casey J. Functional and physical interaction between bicarbonate transport proteins and the transmembrane carbonic anhydrase, CA IX. XXV. International Congress of Physiological Sciences (2005) March 31-April 5, San Diego, CA, Abstract No 366.5
150. Kivela A., Kivela J., Saarnio J., and Parkkila S. Carbonic anhydrases in normal gastrointestinal tract and gastrointestinal tumours. World J Gastroenterol 11 (2005) 155-163
151. Stubbs M., McSheehy P., Griffiths J., and Bashford C. Causes and consequences of tumor acidity and implications for treatment. Mol Med Today 6 (2000) 15-19
152. Raghunand N., Gatenby R., and Gillies R. Microenvironmental and cellular consequences of altered blood flow in tumors. Br J Radiol 76 (2003) S11-S22
153. Newell K., Franchi A., Pouyssegur J., and Tannock I. Studies with glycolysis-deficient cells suggest that production of lactic acid is not the only cause of tumor acidity. Proc Natl Acad Sci USA 90 (1993) 1127-1131
154. 2 gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation. Nat Med 3 (1997) 177-182
155. Helmlinger G., Sckell A., Dellian M., Forbes N., and Jain R. Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism. Clin Cancer Res 8 (2002) 1284-1291
156. Innocenti A., Vullo D., Scozzafava A., Casey J., and Supuran C. Carbonic anhydrase inhibitors interaction of isozymes I, II, IV, V, and IX with carboxylates. Bioorg Med Chem Letters 15 (2005) 573-578
157. Martinez-Zaguilan R., Seftor E., Seftor R., Chu Y., Gillies R., and Hendrix M. Acidic pH enhances the invasive behavior of human melanoma cells. Clin Exp Metastasis 14 (1996) 176-186
158. Brown D., Verbavatz J., Valenti G., Lui B., and Sabolic I. Localization of the CHIP28 water channel in reabsorptive segments of the rat male reproductive tract. Eur J Cell Biol 61 (1993) 264-273
159. Clulow J., Jones R., and Hansen L. Micropuncture and cannulation studies of fluid composition and transport in the ductuli efferentes testis of the rat: Comparisons with the homologous metanephric proximal tubule. Exp Physiol 79 (1994) 915-928
160. Ilio K., and Hess R. Structure and function of the ductuli efferentes: A review. Microsc Res Tech 29 (1994) 432-467
161. Fisher J., Turner K., Fraser H., Saunders P., Brown D., and Sharpe R. Immunoexpression of aquaporin-1 in the efferent ducts of the rat and marmoset monkey during development, its modulation by estrogens, and its possible role in fluid resorption. Endocrinology 139 (1998) 3935-3945
162. Nielsen S., Smith B., Christensen E., Knepper M., and Agre P. CHIP28 water channels are localized in constitutively water-permeable segments of the nephron. J Cell Biol 120 (1993) 371-383
163. Tsuruoka S., Swenson E., Petrovic S., Fujimura A., and Schwartz G. Role of basolateral carbonic anhydrase in proximal tubular fluid and bicarbonate absorption. Am J Physiol Renal Physiol 280 (2001) F146-F154
164. Hynninen P., Hamalainen J., Pastorekova S., Pastorek J., Waheed A., Sly W., et al. Transmembrane carbonic anhydrase isozymes IX and XII in the female mouse reproductive organs. Reprod Biol Endocrinol 2 (2004) 73
165. Casslen B., and Nilsson B. Human uterine fluid, examined in undiluted samples for osmolarity and the concentrations of inorganic ions, albumin, glucose, and urea. Am J Obstet Gynecol 150 (1984) 877-881
166. Casslen B. Uterine fluid volume. Cyclic variations and possible extrauterine contributions. J Reprod Med 31 (1986) 506-510
167. Ge Z., and Spicer S. Immunocytochemistry of ion transport mediators in the genital tract of female rodents. Biol Reprod 38 (1988) 439-452
168. Deachapunya C., Palmer-Densmore M., and O'Grady S. Insulin stimulates transepithelial sodium transport by activation of a protein phosphatase that increases Na-K ATPase activity in endometrial epithelial cells. J Gen Physiol 114 (1999) 561-574
169. Skinner M., MacLaren L., and Wildeman A. Stage-dependent redistribution of the V-ATPase during bovine implantation. J Histochem Cytochem 47 (1999) 1247-1254
170. Li X., Yu H., and Koide S. The water channel gene in human uterus. Biochem Mol Biol Int 32 (1994) 371-377
171. Seki G., Coppola S., Yoshitomi K., Burckhardt B., Samarzija I., Muller-Berger S., et al. On the mechanism of bicarbonate exit from renal proximal tubular cells. Kidney Int 49 (1996) 1671-1677
172. Oosterwijk E., Debruyne F., and Schalken J. The use of monoclonal antibody G250 in the therapy of renal-cell carcinoma. Semin Oncol 22 (1995) 34-41
173. Steffens M., Oosterwijk E., Zegwaart-Hagemeier N., van't Hof M., Debruyne F., Corstens F., et al. Immunohistochemical analysis of intratumoral heterogenity of [131 I] cG250 antibody uptake in primary renal cell carcinomas. Br J Cancer 78 (1998) 1208-1213
174. Steffens M., Boerman O., Oyen W., Kniest P., Witjes J., Oosterhof G., et al. Intratumoral distribution of two consecutive injections of chimeric antibody G250 in primary renal cell carcinoma: Implications for fractionated dose radioimmunotherapy. Cancer Res 59 (1998) 1615-1619
175. Luiten R., Coney L., Fleuren G., Warnaar S., and Litvinov S. Generation of chimeric bispecific G250/anti-CD3 monoclonal antibody, a tool to combat renal cell carcinoma. Br J Cancer 74 (1996) 735-744
176. Luiten R., Warnaar S., Schuurman J., Pasmans S., Latour S., Daeron M., et al. Chimeric immunoglobulin E reactive with tumor-associated antigen activates human Fc epsilon RI bearing cells. Hum Antibodies 8 (1997) 169-180
177. Blok V., Daha M., Tijsma O., Harris C., Morgan B., Fleuren G., et al. A bispecific monoclonal antibody directed against both membrane-bound complement regulator CD55 and the renal tumor-associated antigen G250 enhances C3 deposition and tumor cell lysis by complement. J Immunol 160 (1998) 3437-3443
178. Vissers J., De Vries I., Schreurs M., Engelen L., Oosterwijk E., Figdor C., et al. The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes. Cancer Res 59 (1999) 5554-5559
179. Ringhoffer M., Muller C., Schenk A., Kirsche H., Schmitt M., Greiner J., et al. Simultaneous expression of T-cell activating antigens in renal cell carcinoma: Implications for specific immunotherapy. J Urol 171 (2004) 2456-2460
180. Tso C., Zisman A., Pantuck A., Calilliw R., Hernandez J., Paik S., et al. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor. Cancer Res 61 (2001) 7925-7933
181. Uemura H., Okajima E., Debruyne F., and Oosterwijk E. Internal image anti-idiotype antibodies related to renal-cell carcinoma-associated antigen G250. Int J Cancer 56 (1994) 609-614
182. Uemura H., Beniers A., Okajima E., Debruyne F., and Oosterwijk E. Vaccination with anti-idiotype antibodies mimicking a renal cell carcinoma-associated antigen induces tumor immunity. Int J Cancer 58 (1994) 555-561
183. Uemura H., Okajima E., Debruyne F., and Oosterwijk E. Anti-tumor effect induced by vaccination with anti-idiotype antibodies in 7 mice with established human renal cell carcinoma xenografts. Urol Oncol 1 (1995) 73-79
184. Weijtens M., Willemsen R., Valerio D., Stam K., and Bolhus R. Single chain Ig/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle their lytic capacity. J Immunol 157 (1996) 836-843
185. Weijtens M., Willemsen R., van-Krimpen B., and Bolhuis R. Chimeric scFv/gamma receptor-mediated T-cell lysis of tumor cells is coregulated by adhesion and accessory molecules. Int J Cancer 77 (1998) 181-187
186. Scozzafava A., Mastrolorenzo A., and Supuran C. Modulation of carbonic anhydrase activity and its applications in therapy. Expert Opin Ther Patents 14 (2004) 667-702
187. Teicher B., Liu S., Liu L., Holden S., and Herman T. A carbonic anhydrase inhibitor as a potential modulator of cancer therapies. Anticancer Res 13 (1993) 1549-1556
188. Parkkila S., Rajaniemi H., Parkkila A., Kivela J., Waheed A., Pastorekova S., et al. Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro. Proc Natl Acad Sci USA 97 (2000) 2220-2224
189. Pastorekova S., Casini A., Scozzafava A., Vullo D., Pastorek J., and Supuran C. Carbonic anhydrase inhibitors: The first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX. Bioorg Med Chem Lett 14 (2004) 869-873
190. Cecchi A., Hulikova A., Pastorek J., Pastorekova S., Scozzafava A., Winum J., et al. Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors. J Med Chem 48 (2005) 4834-4841
191. Pastorekova S., Vullo D., Casini A., Scozzafava A., Pastorek J., Nishimori I., et al. Carbonic anhydrase inhibitors: Inhibition of the tumor-associated isozymes IX and XII with polyfluorinated aromatic/heterocyclic sulfonamides. J Enzyme Inhib Med Chem 20 (2005) 211-217
192. Winum J., Cecchi A., Montero J., Innocenti A., Scozzafava A., and Supuran C. Carbonic anhydrase inhibitors. Synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with boron-containing sulfonamides, sulfamides, and sulfamates: Toward agents for boron neutron capture therapy of hypoxic tumors. Bioorg Med Chem Lett 15 (2005) 3302-3306
193. Garaj V., Puccetti L., Fasolis G., Winum J., Montero J., Scozzafava A., et al. Carbonic anhydrase inhibitors: Novel sulfonamides incorporating 1,3,5-triazine moieties as inhibitors of the cytosolic and tumour-associated carbonic anhydrase isozymes I, II and IX. Bioorg Med Chem Lett 15 (2005) 3102-3108
194. Puccetti L., Fasolis G., Cecchi A., Winum J., Gamberi A., Montero J., et al. Carbonic anhydrase inhibitors: Synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating thioureido-sulfanilyl scaffolds. Bioorg Med Chem Lett 15 (2005) 2359-2364
195. Gerweck L. Tumor pH: Implications for treatment and novel drug design. Semin Radiat Oncol 8 (1998) 176-182
196. Raghunand N., He X., van Sluis R., Mahoney B., Baggett B., Taylor C., et al. Enhancement of chemotherapy by manipulation of tumour pH. Br J Cancer 80 (1999) 1005-1011
197. Lim H., Ahn M., Chung H., Gardner T., Kao C., Lee S., et al. Tumor-specific gene therapy for uterine cervical cancer using MN/CA9-directed replication-competent adenovirus. Cancer Gene Ther 11 (2004) 532-538
198. Durrbach A., Angevin E., Poncet P., Rouleau M., Chavanel G., Chapel A., et al. Antibody-mediated endocytosis of G250 tumor-associated antigen allows targeted gene transfer to human renal cell carcinoma in vitro. Cancer Gene Ther 6 (1999) 564-571
199. Deas O., Angevin E., Cherbonnier C., Senik A., Charpentier B., Levillain J., et al. In vivo-targeted gene delivery using antibody-based nonviral vector. Hum Gene Ther 13 (2002) 1101-1114
200. Dachs G., Patterson A., Firth J., Ratcliffe P., Townsend K., Stratford I., et al. Targeting gene expression to hypoxic tumour cells. Nat Med 3 (1997) 515-520
201. Camenisch G., Stroka D., Gassmann M., and Wenger R. Attenuation of HIF-1 DNA-binding activity limits hypoxia-inducible endothelin-1 expression. Pflügers Arch Eur J Physiol 443 (2001) 240-249
202. Potter C., and Harris A. Hypoxia inducible carbonic anhydrase IX, marker of tumor hypoxia survival pathway and therapy target. Cell Cycle 3 (2003) 164-167
203. Gatenby R., and Gillies R. Why do cancers have high aerobic glycolysis?. Nat Rev 4 (2004) 891-898